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High blood pressure affects the lives of approximately 23 million Ameri-
cans . BUSM scientist Haralambos P. Gavras, M.D., is investigating new 
medications that will effectively control hypertension without causing 
undesirable side effects. See story on page 3. 
BUSM researchers Robert G. Feldman, M.D., and Julia Salas administer a nerve conduction 
velocity test on a worker to detect possible nerve damage from lead exposure. (Photo by 
Bradford F. Herzog) 
Lead exposure study in N.H. factory 
seeks means to protect workers 
The nervous system is particularly vul-
nerable to the toxic effects of certain 
heavy metals, solvents and insecti-
cides. In some industries, workers are 
unwittingly exposed for long periods of 
time before clinical manifestations are 
noted. 
Outbreaks of illness and damage 
to the nervous system resulting from 
these intoxications have been docu-
mented by environmental and epide-
miological health research. Chronic 
low-level exposures, however, may go 
unrecognized as potential victims of 
such occupational hazards continue 
on the job, thus creating the necessity 
of standardizing screening methods 
for early detection of neurotoxic 
effects. 
The Department of Neurology at 
Boston University School of Medicine 
has detected subclinical damage 
among industrial workers and school-
children exposed to lead and other 
neurotoxins by utilizing sensitive 
continued on page 5 
BUSM research 
sheds new light on 
gallstone formation 
Scientists have been trying for the 
past 30 years to determine the mecha-
nism by which gallstones are formed. 
There is good reason for that ongoing 
interest: At least 10,000 deaths in the 
United States each year are attributa-
ble to cholesterol gallstones or the 
complications arising from them. Gall-
bladder removal, necessitated by gall-
stones, is probably the most 
frequently performed general surgical 
procedure in this country, with related 
hospitalization costs running into bil-
lions of dollars. 
A research team headed by Lester 
F. Williams Jr., M.D., chairman of the 
Division of Surgery at Boston Univer-
sity School of Medicine, is now 
engaged in a study funded by the 
National Institutes of Health that is 
addressing some key questions about 
the enigma of cholesterol gallstone 
formation. 
"The study concerns the relation-
ship between the contractile function 
of the gallbladder and the formation of 
gallstones," said Williams, who also is 
surgeon-in-chief at University Hospital 
and director of Surgical Services at 
Boston City Hospital. "It is hoped that 
the study will explain why people 
develop gallstones, and it thus could 
lead to methods of prevention and 
nonsurgical treatment." 
In a sense, focusing on the gallblad-
der in terms of gallstone production 
continued on page 2 
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Gallstone formation... 
continued from page 1 
represents a full circle in the investiga-
tion of the disorder, Williams 
explained. 
Largely as a result of discoveries 
some 15 years ago by a BUSM 
research team headed by Donald M. 
Small, M.D., a professor of medicine 
and biochemistry and director of the 
Biophysics Institute in the School's 
Housman Medical Research Center, 
researchers shifted their focus from 
the gallbladder to the liver, when it was 
discovered that the proportions of the 
biliary lipids secreted by the liver—bile 
salts, cholesterol and phospholipids— 
governed the formation of cholesterol 
gallstones. Bile salts and phospholi-
pids prevent cholesterol from precipi-
tating out of solution and forming 
stones. When there is a relative defi-
ciency of bile salts and phospholipids, 
or a relative excess of cholesterol, 
there is a potential for cholesterol gall-
stones to form. The discovery of this 
chemical balancing act led 
researchers back to the liver, where 
the biliary lipids are manufactured and 
their proportions in bile are 
determined. 
"Our research team has taken a dif-
ferent approach by looking at the con-
traction rate of the gallbladder as a 
factor in determining the lipid content 
of bile," Williams said. Normally, he 
explained, bile salts are emptied from 
the gallbladder into the small intestine, 
reabsorbed, and returned to the liver, 
where they are re-secreted. During 
this enterohepatic cycle, as it is called, 
the liver synthesizes replacements for 
the bile salts that have been lost 
through excretion. Since the gallblad-
der serves as a reservoir for bile, the 
rate at which it empties its contents 
into the intestine can greatly influence 
how much bile goes through the 
absorption and re-secretion cycle. 
This, in turn, affects the feedback 
mechanisms that signal the liver to 
increase or decrease bile salt 
synthesis. 
Researcher Wayne W. LaMcrte, M.D., 
mixes solution used in the study of the 
choiesterol gaiistone formation process. 
(Photo by Bradford F. Herzog) 
To study the motor physiology of the 
gallbladder, the BUSM team first con-
ducted in vitro studies using slices of 
guinea pig gallbladder. The tissue 
slices were placed in an apparatus 
that measures changes in muscle ten-
sion. By applying various solutions to 
the tissue, the researchers were able 
to precisely describe the contractile 
properties of gallbladder tissue in dif-
ferent chemical environments. 
Williams and his group now have 
begun the second phase of the study, 
which entails a series of/n wVo experi-
ments using baboons. Baboons have 
been selected for the experiments 
because their bile chemistry is almost 
identical to that of humans. The 
researchers insert catheters into the 
baboons' gallbladders and into other 
parts of their biliary tree, so that they 
can apply various physiological stimuli 
and measure the gallbladder 
contractions. 
"The in vivo studies hopefully will 
shed some light on the feedback 
mechanism that controls the synthesis 
of bile salts in the liver," Williams said. 
"The experiments also will help us 
correlate changes in gallbladder filling 
and emptying with changes in the bile 
salt feedback mechanism. This infor-
mation may represent an important 
extension of the studies by Dr. Small 
and his associates." 
Once the second phase of the 
research is completed, Williams 
hopes to have a clear understanding 
of how changes in gallbladder con-
tractile functions can alter the propor-
tion of biliary lipids produced in the 
liver and possibly induce gallstone for-
mation. This understanding could lead 
to a rationale for dissolving existing 
gallstones and preventing the forma-
tion of new ones. The options for treat-
ing cholesterol gallstones might 
eventually include drug therapy in 
addition to surgery, which is now the 
primary mode of treatment available 
to physicians. 
Other School of Medicine faculty 
members working on the study include 
Desmond H. Birkett, M.D., an assist-
ant professor of surgery, and Wayne 
W. LaMorte, M.D., a research asso-
ciate.—Steven J. Bennett 
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Scientist continues 
BUSM tradition 
in seeking control 
of blood pressure 
In the late 1940s, a Boston University 
School of Medicine research team led 
by Robert W. Wilkins, M.D., success-
fully tested the first medication that 
could be counted on to lower blood 
pressure with any safety and consis-
tency—a preparation of the root of the 
rauwolfia plant found in India. 
In 1957, the same BUSM team was 
the first in the world to use diuretic 
therapy in the treatment of hyperten-
sion. Oral diuretics now represent the 
most widely used agents in the treat-
ment of mild cases of high blood 
pressure. 
Today, Haralambos P. Gavras, M.D., 
a professor of medicine at the School, 
is researching new medications that 
will treat the cause of high blood pres-
sure instead of its effects. "It is much 
better to treat the dysfunction rather 
than the results of that dysfunction," 
said Gavras, who is conducting his 
research in the Housman Medical 
Research Center at the School of 
Medicine. 
An estimated 23 million Ameri-
cans—or approximately 14 percent— 
have high blood pressure. The dis-
ease has been implicated as the most 
important risk factor for heart attack 
and stroke. More than 90 percent of 
people who suffer strokes have high 
blood pressure; further, reduction of 
blood pressure leads to a marked 
decrease in the rate of strokes—even 
among people who have already had 
strokes. 
For years, treatment of hyperten-
sion has relied chiefly on drugs that 
were effective in lowering abnormally 
high blood pressure rates by interfer-
ing with the natural sympathetic ner-
vous system reflexes, blunting the 
brain's capacity to respond to such 
stresses as fear, cold, pain and anxi-
ety. Those medications, however. 
produced undesirable side effects, 
ranging from dryness of the mouth to 
depression, drowsiness and impo-
tence in men. 
Gavras, who is also chief of the 
Hypertension Section at Boston City 
Hospital, believes that the key to con-
trolling high blood pressure lies in 
blocking the body's production of a 
hormone known as angiotensin II. 
Angiotensin II is an extremely 
potent substance that constricts small 
blood vessels, causing blood pressure 
to rise. If the production of this sub-
stance could be inhibited, Gavras 
hypothesized, then blood flow to vital 
organs would be increased and blood 
pressure would be lowered. 
Angiotensinogen, which is found in 
the blood, combines with renin, an 
enzyme produced by the kidneys, to 
form a harmless substance known as 
angiotensin I. When angiotensin I 
combines with the enzyme angioten-
sin-converting-enzyme (ACE), angio-
tensin II is the result. By reducing the 
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angiotensin II 
This diagram shows how renin from the kidneys combines with angiotensinogen, which is 
produced in the iiver, to form angiotensin i. Angiotensin-converting-enzyme, which is 
released by endothelial cells In the small vessels of the lungs and other organs, transforms 
angiotensin I into angiotensin li. (BUSM Department of Medicine diagram) 
action of ACE, constriction of the 
arteries would be discouraged, thus 
promoting arterial dilation. 
Three years ago, Gavras led a team 
of BUSM investigators in the research 
of the first oral preparation to lower 
blood pressure by inactivating ACE. 
This drug, now known as captopril, 
proved to be a major success in the 
treatment of hypertension and con-
gestive heart failure, according to 
Gavras. High blood pressure, he 
explained, is a leading cause of con-
gestive heart failure. 
The BUSM research team was the 
first to test the compound successfully 
in humans. The development was 
described by Aram Chobanian, M.D., 
director of the University's Cardiovas-
cular Institute, as "potentially one of 
the most important breakthroughs in 
the treatment of hypertension since 
diuretics." 
Similar agents that Gavras tested 
prior to captopril included teprotide, a 
polypeptide isolated from the venom 
of a poisonous Brazilian snake, 
Bothrops jararaca. The venom was 
synthesized in a form pure enough for 
human use, but had to be adminis-
tered by injections every six to eight 
hours. This medication fought both 
high blood pressure and congestive 
heart failure, but its prohibitive cost, 
combined with the necessity of taking 
the drug by injections, limited its thera-
peutic potential. However, studies 
using the compound brought to atten-
tion the important role of angiotensin 
in various hypertensive diseases. 
Captopril was another major discov-
ery, but its serious side effects limit its 
use to only severely hypertensive peo-
ple, Gavras said. Those side effects, 
which occur in approximately 12 per-
cent of patients using the drug, include 
a toxic reaction and skin rash. There-
fore, use of captopril has been 
approved by the Food and Drug 
Administration to treat someone who 
takes two to three antihypertensive 
medications but still has high blood 
pressure, or for a patient whose treat-
ment for congestive heart failure has 
been unsuccessful. 
Gavras is now researching a new 
compound that will work in the same 
way as captopril, but hopefully without 
the medication's side effects. 
"Angiotensin-converting-enzyme 
inhibition has proven useful in the 
treatment of severe hypertension and 
congestive heart failure," Gavras said. 
"The main limitation of captopril is the 
high frequency of drug intolerance, 
attributable to the special chemical 
structure of the captopril molecule. 
"If we can find a new compound that 
inhibits angiotensin production, with-
out resulting in undesirable reactions," 
Gavras concluded, "then I predict we 
will see a profound decrease in mor-
tality rates due to hypertension and 
heart failure." 
In addition to Gavras, the research 
team includes Irene Gavras, M.D., and 
Charles Tifft, M.D., both assistant pro-
fessors of medicine; Thomas Ryan, 
M.D., a professor of medicine and 
head of the Section of Cardiology at 
University Hospital, a principal teach-
ing hospital of the School, and David 
Faxon, M.D., an instructor in medicine. 
The team is working under grants from 
the National Heart, Lung and Blood 
Institute and the Squibb Institute. 
—Susan B. Saperstein 
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Lead exposure study... 
continued from page 1 
neurophysiologlcal techniques that 
measure the speed at which an 
impulse travels along a nerve. 
Earlier studies by the department, 
headed by Robert G. Feldman, M.D., 
found nerve and brain damage in 
children exposed to lead, even when 
blood lead levels were not significantly 
elevated. Smelter workers and steel 
burners also were studied by the 
BUSM occupational neurology team. 
By using clinical neurological exam-
inations, nerve conduction velocity 
and neuropsychological test batteries, 
the BUSM team made important dis-
coveries about the effects of chronic 
exposure to lead, arsenic and other 
toxic substances on the nervous sys-
tem. The studies have taken place in 
such diverse locales as Charlestown 
and Quincy, Mass., Fairbanks, Alaska, 
Tacoma, Wash., Kellogg, Idaho, and 
sites in Oklahoma and Iowa. 
The BUSM research team now is 
conducting a detailed analysis of the 
methodology used in the screenings in 
an effort to standardize the techniques 
used to detect early neurotoxic effects. 
The effort is part of a three-year study 
funded by the National Institute for 
Occupational Safety and Health. 
An ideal setting for a controlled 
study was found in Franklin, N.H., 
where a lead foundry and a valve 
manufacturing company are located 
on the same grounds. Workers in the 
foundry are being studied for toxic 
effects of lead to which they are 
exposed daily, while their counter-
parts, who are not exposed to lead in 
their working environments but come 
from similar backgrounds, are being 
studied as control subjects. 
"This study represents the ultimate 
in applied neurophysiology and toxi-
cology," said Feldman, principal inves-
tigator for the study. 
"The study is not only to ascertain 
safe limits of exposure to lead and to 
identify individuals who are possibly 
at risk, but also to try to assist the 
employer in his efforts to protect the 
worker," he explained. Feldman is a 
professor of neurology and pharma-
cology at BUSM and chief of neurol-
ogy at University Hospital in Boston. 
"We want to identify the most sensi-
tive, specific and reproducible screen-
ing methods for detecting disturbed 
nervous-system function in workers 
exposed to lead," Feldman explained. 
"We also want to develop a stan-
dard protocol for the performance of 
electrodiagnostic and psychological 
testing, to establish criteria for eval-
uating test reliability, and to simplify 
such a protocol so that it might be 
employed reliably by a properly 
trained technician," he said. 
/-
As part of the program, which is 
being conducted by BUSM in conjunc-
tion with the Harvard School of Public 
Health, a team of 10 medical experts 
traveled to the foundry site in May and 
June to begin the series of physical, 
neurological and psychological exami-
nations on 112 participating workers. 
The data are being analyzed by com-
puter and will be compared to the find-
ings of follow-up studies to be done 
over the next three years. 
In addition to a complete physical 
examination, which includes blood 
and urine tests to determine the level 
of lead in the body, the screening 
includes examination of the head and 
spine for evidence of trauma, as well 
A member of the BUSM research team, left, conducts a finger reaction test on a Webster 
Valve Co. employee. (Twin Rivers Publishing Inc. photo) 
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as an assessment of the sensory and 
motor functions and the reflex system. 
The tests also include psychological 
assessments regarding memory, intel-
ligence, attention span, perception 
and manual dexterity. 
"This protocol, when developed, 
could have broad application in the 
evaluation of occupational exposure 
to all neurotoxins," Feldman said. 
Previous studies conducted by 
Feldman and the School of Medicine 
researchers found adverse physiologi-
cal, neurological and psychological 
reactions among children and adults 
who had been exposed to even 
low doses of lead over a period of 
time in their homes or industrial 
environments. 
For example, one study found that 
behavioral disturbances were eight 
times more frequent in children 
exposed to lead than among children 
in a control group. Short attention 
spans and impulsive or uncontrolled 
behavior were among the most fre-
quently noted disturbances. 
Other studies by Feldman's depart-
ment have found that apathy, irritabil-
ity, delirium, seizures and confusion 
can result from chronic lead exposure. 
Clumsiness and awkward hand-eye 
coordination and delays in bodily 
response times also were found 
among those exposed to lead, as 
was a decline in intellectual function-
ing, particularly in memory. 
In addition to developing clinical 
neurophysiologlcal techniques to 
screen persons with toxic neuropathy, 
BUSM researchers have devised a 
computerized model of nerve conduc-
tion velocity distributions that can 
detect not only if a nerve is affected. 
but also can define the proportion of 
large or small nerve fibers affected. 
This electronic method provides infor-
mation similar to that which would be 
provided by a nerve biopsy. The tech-
nique was developed by Daniel Sax, 
M.D., a BUSM professor of neurology, 
Zsoldt Kovacs, Ph.D., a research 
instructor in neurology, and Timothy 
Johnson, Ph.D., a lecturer in 
neurology. 
The occupational neurology 
research team also has applied stan-
dardized and innovative neuropsy-
chological tests to find early signs 
of dementia that may result from 
chronic exposure to carbon monoxide, 
methyl chloride, benzene and other 
toxic substances. This research is in 
keeping with the long tradition of 
research in neuropsychology in the 
BUSM Department of Neurology, 
where pioneering contributions have 
been made by Harold Goodglass, 
Ph.D., a professor of neurology 
(neuropsychology) and his staff, 
concerning memory and cognitive 
functions.—Marge Dwyer 
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